Strattera vs Intuniv (Guanfacine): Non-Stimulant ADHD Options Compared

Strattera (atomoxetine) and Intuniv (guanfacine extended-release) are the two most commonly prescribed FDA-approved non-stimulant ADHD medications — but they're fundamentally different drugs with different mechanisms, different best-fit patient profiles, and different roles in the ADHD treatment algorithm. Strattera is a selective norepinephrine reuptake inhibitor designed specifically for ADHD; Intuniv is an alpha-2A adrenergic agonist originally developed as an antihypertensive that was later found to improve ADHD symptoms through a completely different neural mechanism. Both are FDA-approved for pediatric and adolescent ADHD; Strattera also has adult indication while Intuniv's adult use is generally off-label. Both can be used as monotherapy or as adjuncts to stimulants. The choice between them depends on which ADHD symptom dimensions dominate the clinical presentation, age of patient, comorbidity profile, and tolerability considerations.

This guide compares Strattera and Intuniv on every dimension that matters for the non-stimulant ADHD treatment decision. We cover the conceptual framework that these are "two tools for different jobs" rather than directly competing options, the mechanism-level contrast between selective NRI and alpha-2A adrenergic agonism, the symptom-specific best-fit guidance (Strattera better for attention/executive function, Intuniv better for hyperactivity/emotional dysregulation/sleep), distinct side effect profiles with drowsiness as Intuniv's signature side effect and appetite loss as Strattera's, the combination-with-stimulant scenarios where both medications shine as adjuncts, age-specific considerations especially pediatric vs adult, the onset speed difference (days for Intuniv early effects vs weeks for Strattera full effect), the four symptom cluster classifications mapping presentations to medication choice, Intuniv's historical evolution from hypertension medication to ADHD treatment, the formulation comparison between Intuniv (ER) and Tenex (IR guanfacine), and the bottom-line "two tools for different jobs" framework.

🔄 Two Non-Stimulant Options Compared

The non-stimulant ADHD landscape has expanded substantially:

Strattera (atomoxetine):

• FDA approval 2002 — first non-stimulant ADHD medication.
• Pediatric (6+), adolescent, adult ADHD indications.
• Selective norepinephrine reuptake inhibitor.
• Standard adult dose 40-100 mg morning.
• 4-6 weeks to full effect.
• Effect size Cohen's d 0.6-0.7 pediatric, 0.4-0.6 adult.

Intuniv (guanfacine ER):

• FDA approval 2009 (extended-release formulation for ADHD).
• Pediatric (6-17) ADHD indication.
• Adult use largely off-label.
• Selective alpha-2A adrenergic agonist.
• Pediatric dose 1-4 mg morning.
• 1-2 weeks for initial effect, 3-4 weeks for full effect.
• Effect size Cohen's d 0.6-0.7 pediatric.

Kapvay (clonidine ER): Related alpha-2 agonist also FDA-approved for pediatric ADHD; similar mechanism to Intuniv but less selective for alpha-2A vs alpha-2B,C subtypes. Often used interchangeably with Intuniv in pediatric practice. Not covered separately in this article but considerations are similar.

Qelbree (viloxazine ER): Newest FDA-approved non-stimulant (2021); SNRI/serotonin modulator. Approved for both pediatric and adult ADHD. See Strattera vs Qelbree when available for comprehensive comparison.

The four FDA-approved non-stimulant ADHD medications (Strattera, Intuniv, Kapvay, Qelbree) provide options for patients who can't tolerate or shouldn't use stimulants. They're not interchangeable — different mechanisms suit different patients.

🧬 Alpha-2 Agonist vs Selective NRI

Mechanism-level differences explain the symptom-specific patterns:

Strattera (atomoxetine) mechanism:

• Selective norepinephrine reuptake inhibitor (NRI). Binds NET with high affinity (10× more NET than DAT).
• Increases synaptic norepinephrine throughout the brain by preventing reuptake.
• Indirectly elevates prefrontal dopamine via NET (which handles DA reuptake in PFC).
• Net effect: Enhanced norepinephrine and prefrontal dopamine signaling — particularly relevant for attention, executive function, working memory.
• Continuous 24-hour coverage at steady state.
• Not sedating — neutral on alertness or mildly activating.

Intuniv (guanfacine) mechanism:

• Selective alpha-2A adrenergic receptor agonist. Binds alpha-2A receptors (primarily in prefrontal cortex) and activates them.
• Alpha-2A activation in PFC strengthens prefrontal cortex regulation. Improves executive function, attention regulation, and behavioral inhibition through different mechanism than NRI.
• Alpha-2 activation peripherally reduces sympathetic outflow — original antihypertensive mechanism reduces blood pressure and heart rate.
• Net effect: Enhanced prefrontal cortex regulation + reduced sympathetic tone — relevant for impulse control, emotional regulation, behavioral self-regulation.
• Once-daily extended-release provides 24-hour coverage.
• Sedating particularly initially due to alpha-2 activation in locus coeruleus.

The mechanism comparison summary:

• Both target norepinephrine system but at different levels — Strattera at reuptake (presynaptic), Intuniv at receptor (postsynaptic).
• Strattera enhances NE signaling throughout brain; Intuniv specifically activates alpha-2A receptors in PFC.
• Strattera produces neutral/activating subjective effect; Intuniv produces calming/sedating effect.
• This calming effect underlies Intuniv's efficacy for hyperactivity, impulsivity, emotional dysregulation.
• This activating profile of Strattera suits attention and executive function without behavioral component.
• Combinations work because mechanisms differ — stimulant + non-stimulant covers complementary pathways.

🎯 Best for Whom: Behavioral Issues vs Inattention

The clinical pattern of who benefits most from each medication:

Strattera is better for:

• Patients with predominantly inattentive ADHD presentation.
• Adults with executive function difficulties (task initiation, planning, working memory).
• Students with attention difficulties affecting academic performance.
• Patients without significant behavioral or emotional dysregulation.
• Adults requiring FDA-approved treatment (Intuniv adult use is off-label).
• Patients who can't tolerate sedation or low blood pressure.
• Patients whose ADHD doesn't include sleep disturbance.

Intuniv is better for:

• Patients with predominantly hyperactive/impulsive ADHD presentation.
• Pediatric patients with prominent behavioral dysregulation, aggression, oppositional behavior.
• Patients with comorbid tic disorders.
• Patients with comorbid anxiety, particularly hyperarousal-driven.
• Patients with ADHD-related sleep difficulties (Intuniv's sedating effect helps sleep).
• Pediatric patients with autism spectrum disorder and ADHD comorbidity (FDA-approved adjunct in this context).
• Adolescents with emotional reactivity and lability.

Both are appropriate alternatives when:

• Patient or family preferences favor non-stimulant treatment.
• Substance abuse history rules out stimulants.
• Cardiovascular concerns make stimulants problematic.
• Patient experienced significant stimulant side effects.
• Patient or family declined Schedule II controlled substance treatment.

⚠️ Side Effects: Drowsiness vs Appetite Loss

The distinctive side effect signatures of each medication:

Intuniv's signature side effect — drowsiness/sedation:

• Sedation in ~30-40% of patients, particularly initially.
• Typically diminishes over 2-4 weeks as tolerance develops.
• Dosing time matters: Morning dosing reduces school/work day sedation; evening dosing maximizes sedating effect for sleep.
• Some patients use sedation strategically — Intuniv at bedtime to help with sleep onset while providing morning carryover for ADHD coverage.
• Cannot drive if sedated — particularly during initial weeks.

Strattera's signature side effect — appetite loss and nausea:

• Nausea ~25-30% — most common Strattera side effect.
• Appetite suppression ~15-20% with modest weight effects.
• GI symptoms including stomach upset.
• Often improves with food — take with substantial breakfast.
• Diminishes over 2-4 weeks but doesn't fully resolve in some patients.

Comprehensive side effect comparison:

Side effect pattern summary:

• Strattera and Intuniv have inverse cardiovascular profiles: Strattera mildly increases HR/BP; Intuniv mildly decreases them.
• Intuniv's cardiovascular effects benefit hypertensive patients but caution against hypotension in low-BP patients.
• Strattera's GI symptoms are signature; Intuniv's sedation is signature.
• Intuniv requires taper to discontinue due to rebound hypertension risk; Strattera doesn't.
• Both have minimal abuse liability and are non-controlled substances.

🤝 Combining Stimulant + Non-Stimulant

One of the most clinically valuable scenarios for both Strattera and Intuniv is as adjunct to stimulants in patients with partial stimulant response:

Stimulant + Strattera combination:

• Used for partial stimulant response when residual ADHD symptoms persist.
• Strattera covers attention/executive function dimensions stimulant doesn't fully address.
• Continuous 24-hour coverage from Strattera covers early morning and evening when stimulant isn't active.
• Mechanism overlap is partial — both affect norepinephrine but stimulant's reward-system effect is unique.
• Side effect addition can occur — combine carefully and monitor.

Stimulant + Intuniv combination:

• FDA-approved adjunct therapy in pediatric ADHD (this is one of Intuniv's FDA indications).
• Intuniv covers behavioral/emotional/sleep dimensions stimulants don't fully address.
• Particularly valuable for pediatric patients with significant behavioral dysregulation alongside ADHD core symptoms.
• Intuniv may counteract stimulant-induced insomnia (sedating effect of Intuniv balances activating effect of stimulant).
• Mechanism differs substantially — alpha-2 activation vs DAT/NET inhibition — making combination synergistic.
• Cardiovascular monitoring: Stimulant raises HR/BP; Intuniv decreases them — combination may produce balanced cardiovascular profile.

Choosing which adjunct:

• Residual inattention/executive function: Add Strattera.
• Residual hyperactivity/impulsivity/emotional dysregulation: Add Intuniv.
• Stimulant-induced insomnia or appetite issues: Add Intuniv (sedation balances activation; less appetite impact).
• Need for FDA-approved adjunct labeling: Intuniv has this; Strattera adjunct use is off-label.

👶 Children vs Adults: Age-Specific Choice

The age-specific considerations:

Pediatric ADHD (6-17 years):

• Both Strattera and Intuniv are FDA-approved for pediatric ADHD.
• Intuniv has particular pediatric niche for hyperactive/impulsive presentations, behavioral dysregulation, comorbid tics, comorbid anxiety, sleep issues.
• Strattera fits pediatric inattentive presentations and executive function difficulties.
• Intuniv is FDA-approved as adjunct to stimulants in pediatric ADHD — clinical use for partial stimulant responders.
• Pediatric SI black box warning for Strattera (Intuniv doesn't have specific warning).
• Both require monitoring for growth, behavior, mood changes.

Adult ADHD (18+):

• Strattera is FDA-approved for adult ADHD.
• Intuniv adult use is largely off-label — pediatric approval only.
• Adult Intuniv off-label use exists for specific scenarios: adult with prominent emotional reactivity, adult with comorbid PTSD/hyperarousal, adult with sleep difficulty.
• Adult patients typically receive Strattera as non-stimulant first choice; Intuniv as later off-label option.
• Insurance coverage straightforward for adult Strattera (FDA-approved); off-label adult Intuniv may face PA challenges.

⏰ Onset of Effect: Days vs Weeks

The onset speed comparison:

Intuniv onset:

• First effects within days — reduced reactivity, improved emotional regulation often detectable in first 1-2 weeks.
• Behavioral effects detectable early at low doses during titration.
• Full effect typically 3-4 weeks at therapeutic dose.
• Daily steady-state coverage from once-daily ER formulation.

Strattera onset:

• No acute effect on first dose.
• Initial benefit 1-2 weeks at therapeutic dose.
• Full effect 4-6 weeks at steady state.
• Patients often abandon Strattera in first 2 weeks before reaching therapeutic effect.

Practical implications:

• Intuniv allows faster assessment of whether medication is working — within 1-2 weeks.
• Strattera requires commitment to 6-week trial before judging effectiveness.
• For acute behavioral crises: Intuniv's faster effect may be advantageous.
• For planning longer-term treatment: Both work eventually.

🧩 Symptom Cluster Classification

Four major ADHD symptom clusters guide medication choice:

Cluster 1 — "Inattention-Dominant." Patient with predominantly inattentive ADHD: difficulty sustaining attention, organizational deficits, executive function difficulties, distractibility. Recommendation: Strattera. NRI mechanism with prefrontal dopamine effect directly addresses attention and executive function.

Cluster 2 — "Hyperactivity-Dominant." Patient with predominantly hyperactive/impulsive ADHD: gross motor restlessness, impulsive actions, difficulty waiting, inability to sit still. Recommendation: Intuniv. Alpha-2A mechanism reduces sympathetic arousal and improves behavioral regulation.

Cluster 3 — "Emotional Dysregulation." Patient with prominent emotional reactivity: emotional outbursts, low frustration tolerance, anger management difficulties, oppositional behavior. Recommendation: Intuniv. Calming effect on sympathetic arousal addresses emotional reactivity directly.

Cluster 4 — "Sleep Disturbance." Patient with ADHD-related sleep onset difficulty: racing thoughts at bedtime, inability to wind down, restless sleep. Recommendation: Intuniv (bedtime dosing strategy). Sedating effect of guanfacine taken at bedtime helps sleep onset while providing next-day ADHD coverage.

📜 Guanfacine Origin & Evolution

The history of guanfacine illustrates how ADHD medications come from unexpected directions:

• 1980s — Antihypertensive development. Guanfacine developed and approved as antihypertensive medication (Tenex) for blood pressure reduction through alpha-2 agonism reducing sympathetic outflow.
• 1990s — Off-label psychiatric exploration. Researchers noticed guanfacine's calming effect could help ADHD, particularly hyperactive/impulsive presentations. Off-label use in pediatric ADHD developed gradually.
• Multiple smaller studies and case series demonstrated ADHD efficacy in 1990s-2000s.
• 2009 — Intuniv approval. Shire developed extended-release guanfacine formulation specifically for ADHD; FDA approved Intuniv for pediatric ADHD monotherapy and adjunct to stimulants.
• 2011 — Adjunct therapy expansion. Intuniv specifically approved for adjunct to stimulants in pediatric ADHD.
• 2014 — Generic Intuniv available. Affordable extended-release guanfacine for ADHD.
• Present (2026): Intuniv established as one of four FDA-approved non-stimulant ADHD options alongside Strattera, Kapvay (clonidine ER), and Qelbree (viloxazine ER).

The "antihypertensive becomes ADHD medication" story is unusual but not unique — clonidine (Kapvay) followed similar trajectory. The shared alpha-2 agonist mechanism that lowers blood pressure also reduces sympathetic arousal in ways relevant to ADHD hyperactivity and emotional regulation.

💊 Intuniv vs Tenex Formulation Comparison

"Guanfacine" includes two formulations that patients sometimes confuse:

Important distinctions:

• Tenex (IR guanfacine) is NOT FDA-approved for ADHD — only for hypertension. ADHD use is off-label.
• Intuniv (ER guanfacine) IS FDA-approved for pediatric ADHD — specific extended-release formulation designed for ADHD.
• Don't substitute Tenex for Intuniv — different pharmacokinetic profiles affect ADHD efficacy and side effect patterns.
• Generic guanfacine ER is equivalent to brand Intuniv.
• Some prescribers use Tenex off-label for ADHD when Intuniv is unavailable or for cost reasons, but this isn't standard practice.

✨ Bottom Line: Two Tools, Different Jobs

The Strattera vs Intuniv decision is fundamentally a "match the tool to the job" choice rather than "which is better overall." Both are FDA-approved pediatric ADHD non-stimulants; both have legitimate clinical roles; neither is universally better. The right choice depends on which ADHD symptom dimensions dominate and the patient's age.

For inattention and executive function dimensions: Strattera. The selective NRI mechanism with indirect prefrontal dopamine effect specifically targets attention regulation and executive function. Effect size Cohen's d 0.6-0.7 pediatric; meaningful clinical improvement in attention-related ADHD symptoms.

For hyperactivity, impulsivity, emotional dysregulation, sleep difficulty, and tic disorder dimensions: Intuniv. The alpha-2A adrenergic mechanism reduces sympathetic arousal and improves behavioral regulation. Effect size Cohen's d 0.6-0.7 pediatric. Calming/sedating profile particularly suited to behavioral and emotional symptoms.

For adult ADHD: Strattera is FDA-approved; Intuniv is off-label for adults. Adult patients typically receive Strattera as non-stimulant first choice. Adult Intuniv off-label use exists for specific scenarios (PTSD comorbidity, emotional reactivity, sleep difficulty) but isn't standard first-line.

For combination with stimulants: Intuniv has specific FDA approval as adjunct to stimulants in pediatric ADHD. Strattera + stimulant combination is also clinically used (off-label) for partial stimulant responders. The right adjunct depends on which residual symptoms persist — inattention/executive function suggests Strattera; behavioral/emotional/sleep suggests Intuniv.

Side effect profiles are distinctive: Strattera's signature is nausea (~25-30%) and appetite suppression; Intuniv's signature is sedation (~30-40%) and modest hypotension. Both diminish over 2-4 weeks but Strattera's GI symptoms don't fully resolve in some patients. Both have inverse cardiovascular effects — Strattera mildly increases HR/BP; Intuniv mildly decreases them.

Onset speeds differ: Intuniv produces first effects within 1-2 weeks; Strattera takes 4-6 weeks for full effect. For acute behavioral situations, Intuniv's faster onset may be advantageous. Strattera requires more patient/family patience for assessment.

The four symptom cluster classifications (Inattention-dominant / Hyperactivity-dominant / Emotional dysregulation / Sleep disturbance) map specific presentations to appropriate medication choice. Mixed presentations benefit from combination therapy.

For comprehensive ADHD treatment context, see Strattera comparison cluster: vs Adderall, vs Vyvanse, vs Concerta, vs Ritalin, vs Modafinil, vs Wellbutrin.

For broader ADHD treatment landscape including off-label modafinil, see Modafinil for ADHD. For modafinil as additional off-label option, Modalert 200 mg provides Schedule IV alternative.

❓ Frequently Asked Questions

📚 References & Further Reading

• FDA prescribing information for Strattera (atomoxetine).
• FDA prescribing information for Intuniv (guanfacine ER).
• FDA prescribing information for Tenex (guanfacine IR).
• Sallee et al., Journal of the American Academy of Child & Adolescent Psychiatry — Intuniv pediatric pivotal trials.
• Wilens et al. — Intuniv ADHD trials.
• Michelson et al., Pediatrics — atomoxetine pediatric trials.
• Biederman et al. — adjunct therapy studies.
• American Academy of Pediatrics — ADHD clinical practice guidelines.
• American Psychiatric Association — guidelines for ADHD treatment.
• CADDRA — adult ADHD treatment algorithm.
• NICE clinical guideline NG87 — ADHD UK guidelines.
• Newcorn et al. — pediatric ADHD non-stimulant comparison.
• Strattera comparison cluster: vs Adderall, vs Vyvanse, vs Concerta, vs Ritalin, vs Modafinil, vs Wellbutrin
• Modafinil cluster: Modafinil for ADHD, Modafinil vs Ritalin, Modafinil vs Vyvanse
• Modalert 200 mg, Modvigil 200 mg, Waklert 150 mg — primary product pages.
• RXshop Editorial Team — content reviewed by licensed pharmacist; for adult patient education, not a substitute for individual medical consultation.